Breaking News, Collaborations & Alliances

ProBioGen, ImmunOs Ink Manufacturing Services Agreement

ProBioGen will support ImmunOs in the development of their biologics using its DirectedLuck Transposase technology

ProBioGen AG, together with ImmunOs Therapeutics AG, signed a manufacturing services agreement for ImmunOs’ novel platform of multitasking biologics. ProBioGen will support ImmunOs in the development of their biologics using its recently launched DirectedLuck Transposase technology and conducting large scale GMP manufacturing. ImmunOs has a pipeline of novel agents in development.   “We are pleased about this confidence in our expertise,” said Wieland Wolf, chief executive officer,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters